Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Income from Continuing Operations of 24417000.0 for Q3 2025, down 34.86% year-over-year from 37485778.43 in Q3 2024, and down 27.49% quarter-over-quarter from 19152000.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 24417000.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 34.86% year-over-year to 24417000.0; the TTM figure through Sep 2025 stood at 78917000.0 (down 26.36% YoY), while the FY2024 annual figure was 51539000.0, up 63.19% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 24417000.0, down from 19152000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9201159.0 in Q1 2022, with the low at 53964679.0 in Q2 2021.
- The 5-year median for Income from Continuing Operations is 19163149.0 (2022), against an average of 23774597.84.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 82.22% in 2022, then plunged 118.07% in 2025.
- Corbus Pharmaceuticals Holdings' Income from Continuing Operations stood at 10433727.0 in 2021, then slipped by 19.68% to 12486612.0 in 2022, then increased by 14.11% to 10725000.0 in 2023, then slipped by 16.86% to 12533000.0 in 2024, then tumbled by 94.82% to 24417000.0 in 2025.
- Business Quant data shows CRBP's Income from Continuing Operations at 24417000.0 in Q3 2025, 19152000.0 in Q2 2025, and 22815000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.42 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -22.82 Mn |
| Dec 31, 2024 | -12.53 Mn |
| Sep 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -23.16 Mn |
| Mar 31, 2024 | -10.46 Mn |
| Dec 31, 2023 | -10.73 Mn |
| Sep 30, 2023 | -30.31 Mn |
| Jun 30, 2023 | -28.96 Mn |
| Mar 31, 2023 | -18.23 Mn |
| Dec 31, 2022 | -12.49 Mn |
| Sep 30, 2022 | -19.16 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -10.43 Mn |
| Sep 30, 2021 | -52.68 Mn |
| Jun 30, 2021 | -53.96 Mn |
| Mar 31, 2021 | -51.75 Mn |
| Dec 31, 2020 | -21.48 Mn |